Merck press release
Merck announced the presentation of results from three pivotal Phase 3 trials evaluating the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg), (MK-8591A)] in adults with HIV-1. The findings were shared in late-breaking presentations at CROI 2026.
— DOR/ISL is the first non-INSTI, two-drug regimen to demonstrate non-inferiority and a similar safety profile at Week 48 to bictegravir/emtricitabine/tenofovir alafenamide in adults living with HIV-1 who had not previously received antiretroviral treatment (MK-8591A-053 trial)
— DOR/ISL maintained virologic suppression at Week 96 in adults with virologically suppressed HIV-1 who switched from other oral antiretroviral therapies, including bictegravir/emtricitabine/tenofovir alafenamide (MK-8591A-051 & MK-8591A-052 trials)
Read the full press release here.
SEE ALSO:
- Infectious Disease Special Edition: DOR/ISL maintains efficacy in both treatment-naive and switch settings through 96 weeks
Source : Merck
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.